Zevra Therapeutics Inc. (ZVRA)
NASDAQ: ZVRA
· Real-Time Price · USD
9.62
0.11 (1.16%)
At close: Aug 22, 2025, 1:44 PM
Zevra Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 74.71M | -3.1M | -35.74M | -33.23M | -19.93M | -16.62M | -15.15M | -14.04M | -5.08M | -11.77M | -9.02M | -6.62M | -24.04M | -1.86M | -2.7M | -1.76M | 6.2M | -10.3M |
Depreciation & Amortization | 1.65M | 1.65M | 1.65M | 1.62M | 1.56M | 1.56M | 787K | 62K | 78K | 79K | 300K | 398K | 181K | 65K | 64K | 65K | 64K | 64K |
Stock-Based Compensation | 2.46M | 3.12M | 4.02M | 6.14M | 2.63M | 2.12M | 2.96M | 1.39M | 749K | 945K | 955K | 911K | 1.51M | 918K | 823K | 620K | 318K | 675K |
Other Working Capital | 1.96M | 2.73M | -2.31M | 1.18M | 1.49M | 671K | -1.03M | 1.13M | 885K | 2.63M | 3.82M | 1.01M | -1.24M | -555K | 90K | -1.48M | 719K | -10.18M |
Other Non-Cash Items | -75.13M | -3.04M | 12M | 7.57M | -1.94M | -3.08M | 5M | 5.77M | -329K | -38K | -122K | 182K | 17.83M | 161K | 75K | 73K | 80K | 232K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -6.63M | -5.56M | 1.37M | n/a | n/a | n/a | n/a | n/a | -66K | -332K | -319K | 16.91M |
Change in Working Capital | -7.29M | -6.84M | 1.83M | -239K | -1.44M | -148K | -3.12M | 7.76M | -5.84M | 7.09M | 3.43M | -1.47M | 346K | -2.77M | 959K | -1.4M | 10.26M | -10.18M |
Operating Cash Flow | -3.6M | -8.22M | -16.25M | -18.14M | -19.11M | -16.16M | -16.16M | -4.63M | -8.7M | -4.04M | -4.46M | -6.6M | -4.17M | -3.48M | -848K | -2.73M | 16.6M | -2.59M |
Capital Expenditures | -213K | -99K | n/a | n/a | n/a | n/a | -72K | -172K | -23K | -29K | -34K | -28K | -15K | -16K | -17K | -4K | -81K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | -30.4M | 44.28M | -34M | n/a | 1.32M | n/a | -14.09M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -150.35M | -7.36M | -14.6M | -41.36M | -129K | 14.79M | 25.43M | -53.78M | 59K | -17.53M | 1.3M | n/a | -20M | -3.83M | -15.42M | n/a | n/a | n/a |
Sales Maturities Of Investments | 12.5M | 18M | 202K | 10.01M | n/a | 14.79M | 15.63M | 9.5M | 34M | n/a | -1.32M | 300K | 1.02M | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 150M | n/a | 8.92M | n/a | n/a | -14.79M | n/a | -44.28M | 34M | -17.53M | -1.32M | 300K | n/a | -3.83M | -15.42M | n/a | n/a | n/a |
Investing Cash Flow | 11.93M | 10.54M | -5.47M | -31.35M | -129K | 14.79M | 10.59M | -44.46M | 34.04M | -17.55M | -63K | 272K | -33.08M | -3.85M | -15.44M | -4K | -81K | n/a |
Debt Repayment | n/a | -372K | -16.29M | n/a | 16.29M | n/a | -1.1M | 26.21M | -322K | 112K | -3K | -2K | 12.8M | -10K | -17K | -23K | -72K | -37.98M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.45M | n/a | n/a | n/a | -4.72M | -2.81M | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | 82.98M | 92K | -889K | n/a | n/a | n/a | 1.27M | -415K | -254K | -407K | 736K | n/a | -39K | 1.97M | 39.82M | 62.99M |
Financial Cash Flow | 1.38M | 1.61M | 796K | 64.77M | 15.33M | 1.22M | 5M | 26.26M | 951K | -3.75M | -257K | -409K | 13.82M | -4.8M | -2.87M | 1.94M | 39.75M | 74.29M |
Net Cash Flow | 10.37M | 3.56M | -20.25M | 14.78M | -3.59M | -200K | -220K | -22.93M | 26.02M | -25.29M | -4.59M | -6.72M | -23.43M | -12.13M | -19.16M | -792K | 56.27M | 71.7M |
Free Cash Flow | -3.81M | -8.32M | -16.25M | -18.14M | -19.11M | -16.16M | -16.23M | -4.8M | -8.73M | -4.07M | -4.5M | -6.63M | -4.19M | -3.5M | -865K | -2.73M | 16.52M | -2.59M |